MicroRNAs (miRs) are small non-coding RNAs that negatively regulate gene expression by binding to the 3` untranslated regions (3`UTR) of their target mRNAs. MiRs were shown to play pivotal roles in tissue development and function and are also involved in the pathogenesis of various diseases including cancer. MicroRNA-206, which belongs to the group of so-called "myomiRs", is one of the most studied miRs thus far. In addition to being involved in skeletal muscle development and pathology, it has also been established that it is involved in the pathogenesis of numerous diseases including heart failure, chronic obstructive pulmonary disease, Alzheimer's disease and various types of cancers. The aim of this review is to provide a complex overview of microRNA-206, including regulating its expression, a brief description of its known functions in skeletal muscle and a complex overview of its roles in the biology and pathology of other tissues, emphasizing its significant diagnostic and therapeutic potential.
Introduction
MicroRNAs (miRNAs) are small non-coding RNAs, first discovered in the C. elegans nematode worm in 1993 [1] . According to the latest release of miRBase [2] 20 years later, there are now over 30,000 known mature miRNA sequences described in 206 species.
MiRNA Biogenesis ( Figure 1 ) consists of several consecutive steps with the first one being transcribing the miRNA from its corresponding gene using RNA-polymerase II/III into the molecule called primary miRNA (pri-miR). In the nucleus, pri-miR is cleaved with Drosha/DGCR8 complex to form a precursor miRNA (pre-miR) that is transported from the nucleus with exportin-5 protein. In the cytoplasm, nuclease Dicer cleaves pre-miR, which leads to the generation of miRNA-miRNA* duplex. MiRNA* is usually degraded even though some miRNA* has been observed to function in a similar way to to miRNAs, i.e. they create a complex with Argonaut (Ago) proteins called (mi)RNA-induced silencing complex (RISC or miRISC). The miRNAs in this complex function as negative regulators of gene expression: they bind to the 3´-untranslated regions (3´-UTR) of their target mRNAs (in accordance with base complementarity) and this then leads either to target mRNA degradation or to translational inhibition [3] . One miRNA usually has more than one target mRNA and one mRNA is usually targeted by more than one miRNA [4] , which leads to the formation of a huge regulatory network which plays a pivotal role in nu-
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This review focuses on microRNA-206 (miR-206), a vertebrate specific miRNA, which is referred to as a skeletal muscle specific myomiR [5] . This miRNA shares the same seed sequence and at least some targets with miR-1 [2] , which also belongs to the myomiR family along with miR-133a, miR-133b, miR-208a, miR-208b and miR-499 ( [6] , Figure 2) ; however miR-1 is expressed in both skeletal and cardiac muscles [7] . MiR-206 is being intensively studied in various contexts: skeletal muscle development [8, 9] , function and pathology [5, 9] , heart failure [10] , various types of cancers [11] [12] [13] and other diseases [14] [15] [16] . The aim of this review is to introduce miR-206, provide a short description of its relevance in skeletal muscle biology as well as offering a more detailed description of this miRNA's role in other conditions while placing special emphasis on its theranostic potential. . Already in the nucleus, microprocessing complex Drosha/DGCR8 cleaves pri-miR to precursor miR (pre-miR) that is transported from the nucleus with Exportin 5. In the cytoplasm, the Dicer claves pre-miR: the passenger strand (miR*) is consecutively degraded and the mature strand (miR) is incorporated into the RNA-induced silencing complex (RISC). Within the RISC, base pairing between miR and target mRNA 3´untranslated region (3´UTR) occurs leading to target mRNA degradation or translational inhibition. 
Regulation of microRNA-206 expression
The gene for human miR-206 (hsa-miR-206) is localized on chromosome 6 in a bicistronic cluster together with the gene for miR-133b [2] . The expression of these microRNAs can be regulated on different levels including chromatin remodeling, transcriptional and posttranscriptional regulation and is also under endocrinological and environmental control.
The chromatin remodeling enzyme, high mobility group box 1 protein (HMGB1), has previously been shown to increase miR-206 levels when injected into the chronically failing hearts of experimental animals [10] . In another cell type, the Th17-lymphocyte, it was reported that miR-206 and miR-133b are co-transcribed together with interleukin (IL)-17 when IL-23 is used [17] . This co-transcription is specific for T-lymphocytes (IL-17 is not detectable in skeletal muscle even after IL-23 stimulation) and may be affected both by chromatin remodeling, since the IL-17 gene is located near the genes for miR-206/133b, and transcription factors (TFs) specific for IL-17, e.g. STAT3 [17] .
Various TFs important for skeletal muscle development have been shown to regulate miR-206 expression during skeletal muscle development; likewise, the proper spatiotemporal expression of these TFs is critical to successfully complete myogenesis [18] . One of the strongest inducers of myogenesis, and therefore also of mir-206, is Myf5 [19] , which acts through MyoD [20] [21] [22] and myogenin [19] with MEF2C enhancement [23] . Negative regulation of miR-206 expression during myogenesis is carried out via myostatin, since myostatin knockout caused upregulation of all myomiRs in experimental animals [24] . Whether this regulation is direct or indirect still remains to be determined. The importance of proper myostatin-mediated negative myogenesis regulation was previously documented on Texel sheep where just one SNP in the 3'UTR of myostatin created a binding site for miR-1/206, resulting in these animals' muscular phenotype [25] . Various autoregulatory loops which add robustness to this TF network have also been described, one of them involving Notch3 protein [23] . Notch3 expression is increased by MyoD at the beginning of muscle differentiation, thus ensuring MEF2C inhibition, which is important in the final stages of myogenesis. When cells are ready to finish the differentiation process, miR-1/206 targets Notch3, thereby inhibiting its function [23] .
In addition to the above mentioned TFs, other molecules and various signal pathways have also been shown to increase or decrease miR-206 expression in various tissues (Figure 3) . Song et al. [26] described a "dual inhibitory mechanism", in which small heterodimer partner (SHP), a known nuclear transcriptional co-repressor, plays a role. In this model, SHP inhibits the expression of estrogen-related receptor γ (ERRγ) which is responsible for Ying Yang 1 (YY1) TF expression. A decrease in YY1 leads to the activation of TF activator protein 1 (AP1) and to an increase in miR-206 expression [26] . A study by Lu et al. [27] lists other significant players involved in this regulatory mechanism: NFκB, miR-29 and miR-1. NFκB stimulates and miR-1/29 inhibits YY1 signaling, thus inhibiting or activating miR-206 expression, respectively [27] . Other signals inhibiting miR-206 expression include e.g. Sonic Hedgehog (Shh) [28] , fibroblast growth factors 2 and 4 (FGF2/FGF4) [29] signaling pathways and tumor growth factor β (TGFβ) [30] . The participation of thyroid hormones in the miR-206 regulation was described in mouse liver and corresponding cell line models [31] and in human skeletal muscle in patients with hypothyroidism [32] . Thyroid hormones and their substituents decrease miR-206 levels and hypothyroidism increases its expression [31, 32] ; accordingly, miR-206 is also proposed to serve as an important mediator of thyroid hormone function since some of the miR-206 targets (e.g. Mup1 and Gpd2) were previously shown to be regulated by thyroid hormones [31] . Additional hormones to be considered in miR-206 regulation are estrogens, as shown in human breast cancer [33] , where miR-206 further targets estrogen receptor α (ERα), i.e. one of the factors responsible for cancer cells' ER-negative phenotype and an element affecting responsiveness to hormonal therapy [33] .
Focusing on posttranscriptional regulation, bone morphogenetic protein 2 (BMP-2) was shown to inhibit pri-miR-206 to mature miR-206 processing [34] . BMP-2 has previously been shown to cause C2C12 myoblast cell lineage differentiation into osteoblasts when supplemented [35] ; this was explained by its inhibition of MyoD and myogenin activity [36] . This study therefore further expands our understanding of the lineage switch process with BMP-2 inhibiting miR-206, myoD and myogenin activity, resulting in the inhibition of myogenic differentiation.
Last but not least, the effect of environmental factors on miR-206 expression needs to be mentioned. Essential aminoacids are known to be important for muscle growth and as such stimulate muscle protein synthesis -along with pri-miR-206 levels [37] . Physical exercise was repeatedly shown not to the affect the circulating miR-206 levels [38, 39] , which may become an advantage when monitoring the course of muscle dystrophies because circulating levels of currently used markers (e.g. creatinkinase) are affected [40, 41] .
Endurance training did not significantly affect the levels of circulating miR-206 either; however, the basal expression of miR-206 in muscle tissue was significantly lower after 12 weeks and it returned to the pre-training values following 2 weeks of withdrawn training [42] . Interestingly, spaceflight has been shown to decrease miR-206 levels [43] . These results indicate that miR-206 is probably not involved in short-term muscle adaptation to physical exercise; however, everyday muscle activity is needed for its sustained expression and this basal expression may be reduced if these stimuli are either withdrawn (spaceflight) or chronically increased (endurance training).
ROLES FOR MicroRNA-206 IN SKELETAL MUSCLE

Myogenesis and muscle regeneration (Figure 4)
Myogenesis is a complex process during which muscle progenitor cells leave the somites and migrate to final body locations where they proliferate and differentiate in order to create skeletal muscle [18] . MiR-206 is currently considered an important part of the myogenesis process in humans [44] , mice [45] , zebrafish [46] , pigs [47, 48] and even common carp [49] . It can be specifically detected in the somites, with the highest expression in mouse embryos being detected 11.5-12.5 days post conception and tending to decrease from the 3rd day after birth [50] . If miR-206 and other miRNAs levels decrease due to Dicer knockout (this knockout results in global downregulation of most miRNAs), mice die prenatally [51] . If muscle-specific Dicer knockout is performed, it results in skeletal muscle hypoplasia and defective fiber morphology indicating the important role of microRNAs in muscle development [52] . The mouse myoblast cell line (C2C12) is the most commonly used cell line for the study of myogenesis. When C2C12 cells are cultured under high serum conditions, they remain in a proliferating state; however, if they are switched to low serum conditions, they begin to differentiate and fuse into myofibers [53] . The importance of miR-206 in myogenesis is highlighted by a study by Kim et al. [45] . This study indicated that even in stable serum conditions, adding miR-206 induces C2C12 cell differentiation and vice versa -if miR-206 is blocked and serum conditions are changed, no differentiation occurs [45] .
Proper miR-206 downregulation and upregulation during different stages of myogenesis is crucial since it targets key molecules like paired box 3 (Pax3) and Pax7, both of which are important TFs for muscle progenitor cell migration and proliferation, respectively [18] . At the right moment, miR-206 needs to be upregulated (via the regulatory pathways described above and including Myf5, MyoD and others') in order to initiate the muscle differentiation program. Inhibiting miR-206 expression using antagomiRs results in a delayed differentiation onset and improper migration of muscle progenitors [54] . Later, during myogenesis, miR-206 targets various genes enabling early and -subsequently -terminal differentiation [9] , e.g. DNA-polymerase α (POL α) [45] , histon deacetylase 4 (HDAC4) [30] , utrophin [21] and connexin 43 (Cx43) genes [55] . Inhibiting POLα is important to terminate the proliferation program [45] at the beginning of differentiation, which is promoted by removing the inhibitory effects of HDAC4 on MEF2C [30] . The downregulation of utrophin seems to be important later in the myogenesis process [21] while follistatin [21] and Cx43 downregulation [55] play an important role in myocyte fusion into myofibers. This process naturally involves additional miRNAs, but a detailed description is clearly outside the scope of this review.
During myogenesis, part of the myoblasts enter quiescence, locate themselves between the basal membrane and sarcolemma [56] and remain in a self-renewing state which maintains their ability to enter the muscle differentiation program in the future if the muscle is injured [18] . In this case, miR-206 levels in SCs are downregulated, thus enabling Pax7 to increase while causing SCs proliferation [57] . After a short time, miR-206 levels return to the pre-injury state and SCs differentiate to replace the damaged rhabdomyocytes. When miR-206 is artificially added to injured skeletal muscle, it promotes muscle healing as shown in rat models in a study conducted by Nakasa et al. [58] .
Innervation, reinnervation and amyotrophic lateral sclerosis (ALS)
In order to properly perform its function, skeletal muscle must be properly innervated; during innervation, skeletal muscle tissue cooperates with axons in order to create neuromuscular junctions (NMJ) ( Figure 5 ). MiR-206 levels were found to be increased in NMJ [59] , facilitating mutual communication between muscle fibers and motoneuron axons by targeting various molecules including brain-derived neurotropic factor (BDNF) and its receptor (p75 NTR ) [60] , HDAC4 [59] and MEF2 [61] . The experiments focused on reinnervation after a sciatic nerve injury showed that miR-206 expression remained unchanged immediately after denervation; however, it increased during the reinnervation process [61] . By targeting MEF2, miR-206 was proposed to affect muscle composition (fiber type) and to constitute one of the sources of the differences observed between healthy and reinnervated muscle [61] . However, these results were not confirmed by a subsequent study where miR-206 levels remained unchanged both after denervation and during reinnervation; the role of other myomiRs was thus emphasized [62] .
Reinnervation has also been intensely studied in amyotrophic lateral sclerosis (ALS) [59, 63] . ALS is a neurodegenerative disease which causes a loss of motoneurons, resulting in the denervation of skeletal muscle, consequent paralysis and death [59, 63] . MiR-206 levels were shown to be upregulated in both mice [59] and humans [63] . In the mouse model, the effects of miR-206 were analyzed in detail using miR-206 knockdown animals. Although the ALS onset in these animals was the same as wild type animals, the progression of ALS was faster, resulting in a more severe phenotype, delayed reinnervation and subsequent over-innervation with motoric axons sprouting beyond the original NMJ area [59] . HDAC4, a miR-206 target was suggested to play a role in these effects and the entire signaling pathway, including miR-206/HDAC4/FGFBP1/FGF, was suggested as an explanation of these processes [59] . In human ALS samples, miR-206 was upregulated in both slow and rapid progression patients and only levels of HDAC4 served to distinguish between these groups, indicating that other signals are also necessary for the reinnervation process [63] .
Muscular dystrophies
Muscular dystrophies (MD) represent a group of heritable diseases whose common sign is muscle weakness, often in a progressive form [64] . The most common X-linked and autosomal dominant MDs are Duchene MD and myotonic dystrophy type 1 (MDT1) respectively [64, 65] . The first study to report the dysregulation of myomiRs in Duchene MD was conducted by McCarthy et al. using mdx mice [66] . The study showed that miR-206 is downregulated in the plantaris muscle, but is increased in the diaphragm, most likely due to the upregulation of MyoD and possibly due to the functional denervation of the regenerating muscle [66] . Roberts et al. further confirmed that miR-206 levels also differ between muscle groups in an experimental animal [67] . It was also shown that miR-206 increase occurs during muscle regeneration [68, 69] and, since the diaphragm is the most affected muscle in mdx mice [66] , high expression of miR-206 may indicate a high regenerative capacity of this muscle. Interestingly, Yuasa et al. reported that in CXMD J dogs, which display a more severe phenotype than mdx mice, miR-206 levels are not increased, which may reflect insufficient regeneration [68] . All of the above mentioned information correlates with a subsequently reported observation, i.e. that miR-206 may be found mostly in satellite cells where it stimulates their differentiation in order to initiate muscle regeneration [70] .
In MDT1, the miR-206 dysregulation and other muscle-specific miRNAs were described several years later [71, 72] . Whether miR-206 levels are upregulated [72] or unchanged [71] still remains to be elucidated by more extensive studies; however, in MDT1 patients, miR-206 is mislocalized within the cell compared to normal muscle tissue [71, 72] .
The above mentioned studies clearly indicate that miR-206 is extensively involved in the pathophysiology of various muscle dystrophies. From a theranostic point of view, miR-206 levels (along with miR-1 and miR-133) were shown to be good serum biomarkers for DMD, correlating even with the severity of the disease [40, 67] . Since their levels are not affected by physical exercise [38] [39] [40] they may serve as more precise and valuable biomarkers than the currently used creatinkinase. Current studies also suggest that miR-206 may be used as a therapeutic tool in muscular dystrophy thanks to its reported pro-differentiating and disease-progression slowing effect [67, 73] (Figure 6 ). (Figure 7) 
MIR-206 IN TUMOR BIOLOGY
Rhabdomyosarcoma
Rhabdomyosarcoma represents the most common soft tissue sarcoma with embryonal RMS (ERMS) being the most common type, followed by alveolar RMS (ARMS) [74] . Both of these tumors express markers specific to skeletal muscle; however, their cells are much less differentiated in comparison with muscle tissue [75] . Although the downregulation of miR-206 (and other myomiRs) has been observed repeatedly in both types, it is more prominent in ARMS, thus partially explaining its less differentiated phenotype and more aggressive clinical behavior [76] [77] [78] .
Experiments reinducing miR-206 in RMS cell lines have led to decreased cell proliferation and migration properties and increased myogenic differentiation [76, 77] . Expression profiling in the RD18 ERMS cell line identified more than 700 mRNA levels to be affected by miR-206 transfection [77] . Cell line experiments were further extended by injecting miR-206 directly into RMS mouse models which caused a significant decrease in tumor mass and an increase in the expression of differentiation markers implicating miR-206 as a RMS therapy [76, 77] .
Clinical trials focusing on the association between miR-206 and RMS have also been conducted, resulting in circulating miR-206 being identified as a potent diagnostic marker: the levels of this microRNA are muscle-specific even if this microRNA is downregulated in RMS tissue and its circulating levels are higher in RMS patients than in healthy controls [79] . MiR-206 also provides information about the prognosis of a patient: tumors expressing lower miR-206 levels are considered more aggressive with a poorer prognosis [80] . 
Breast cancer
Breast cancer is the most common cancer in women [81] . In most cases, ERα is present and provides an enormous theranostic potential: its presence facilitates both disease classification and the tailoring of individual therapy. MicroRNA array analysis identified microRNA deregulations in this cancer [82] with miR-206 being increased in ERα negative and decreased in ERα positive breast cancer [83, 84] . ERα was repeatedly shown to be a target for miR-206 [33, 83, 85, 86] and two miR-206 binding sites were found to be localized in its 3´UTR, along with binding sites for a number of additional miRNAs [33] . Moreover, miR-206 also targets steroid receptor coactivators (SRC)-1 and SRC-3 and TF GATA-3, all of which are part of estrogen-mediated signaling pathways; miR-206-mediated inhibition thus disrupts estrogen signaling on more levels than simply affecting ERα expression [87] .
MiR-206 levels and activity in breast cancer are subject to the influence of numerous factors. Estradiol activation of ERα causes miR-206 downregulation [33] ; however, this regulatory circuitry may be distracted by epidermal growth factor (EGF) signaling (applying both estradiol and EGF does not decrease miR-206) partly through the EGF-receptor/MAPK pathway [87] . On the contrary, miR-206 activity may be increased when ellagic acid is used [88] or when a single nucleotide polymorphism (rs9341070) in ERα 3´UTR is present -as it increases miR-206 binding [33] , or when Ago-2 protein levels are increased -as observed in breast cancer cells [89] . The factors contributing to increased miR-206 activity also contribute to ERα negativity [89] and consequently to a poorer prognosis.
Thus far, applying miR-206 to breast cancer cell lines has been shown to decrease cell growth [83, 85] due to cell cycle arrest [11, 83, 86] and to decrease cell proliferation following estradiol stimulation [86] . Underlying cell growth decrease mechanisms include the cyclinD2 downregulation, an important molecule inducing cell cycle entry [11] and hepatocyte growth factor receptor (MET) downregulation [85] . These results indicate miR-206's future therapeutic potential in breast cancer therapy.
MiR-206 has also been identified as a metastasis-preventing microRNA [90] and its decreased levels have been associated with advanced clinical stages and the presence of lymph node metastasis [91] . Even if its levels do not correlate with prognostic parameters, pre-miR-206 SNP (rs6920648) presence affects patient survival (HR 0.77, p = 0.02), with stronger associations being observed in Caucasians and women with ER+ tumors than in African Americans [92] . However, how exactly this SNP affects miR-206 biogenesis still remains to be clarified.
Other cancers
As miR-206's potential roles in other cancers are currently being intensely studied, only a limited number of studies are currently available ( Table 1) . Some of these studies focus on the microRNA profiling of specific cancers [93] [94] [95] , others evaluate the potential link of miR-206 expression levels to the clinical outcomes of individual patients [96, 97] and still others evaluate the miR-206's potential use in treatment [12, 98] . 
Endometrial cancer
In ERα+ endometrial endometroid carcinoma, miR-206 levels are decreased and correlate negatively with ERα levels.
[101]
Introduction of miR-206 causes cell cycle arrest and affects invasiveness.
Colorectal carcinoma
Lower expression of miR-206 indicates worse prognosis. [96] Prognostic signature of miR-206 and additional four miRs (let-7a, miR-21, miR-135a, miR-335) may be used to detect metastases. Downregulation of miR-206 dysregulates miR-206/KLF-4 feedback loop which is involved in cancer development.
[102, 103]
Gastric cancer
Low expression of miR-206 indicates presence of metastases, venous invasion and higher probability of hematogenous recurrence along with shortened overall survival.
[12, 97]
MiR-206 targeting of cyclinD2 is partially responsible for decrease in cell growth and impaired colony growth of gastric cancer cell lines.
[12]
Lung cancer Low expression of miR-206 was detected in samples with metastasis.
[13] Transfection of miR-206 caused decrease in cell proliferation, migration and invasion and induced apoptosis. Lung carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone increases levels of miR-206 (and miR-133b) in plasma of exposed rats.
[104]
Osteosarcoma
MiR-206 is one of the downregulated microRNAs in osteosarcoma.
[105] Naso-pharyngeal carcinoma MiR-206 is one of 13 identified microRNAs suggested to play important roles in nasopharyngeal [106] carcinoma development. Levels of miR-206 increased when lymph node metastasis were present.
Laryngeal cancer
Levels of miR-206 are downregulated in laryngeal carcinoma patients.
[99] Induction of miR-206 in cancer cell lines causes decrease in viability and invasive potential and increase in apoptosis. Application of miR-206 into mouse model leads to significant decrease in tumor mass.
Ovarian cancer
MiR-206 is higher in CD133+ cells (ovarian cancer stem cells) compared to CD133-cells.
[93]
Prostate cancer
MiR-206 expression does not change during the progression of prostate cancer from intraepithelial neoplasia to metastases.
[107]
Renal cell carcinoma MiR-206 is downregulated in clear cell renal cell carcinoma and inhibits cancer cell proliferation. [94, 108] 
Prolactinoma
Bromocriptine treatment increases levels of miR-206 in prolatinomas which may partly explain bromocriptine-induced apoptosis.
[98]
Vestibular schwannoma
MiR-206 is significantly downregulated in schwannoma cells.
[95]
Glioma and neuroblastoma
MiR-206 is downregulated in tumor cell lines and its transfection leads to apoptosis, in part by targeting Otx2.
[109]
Waldenström macro-globulinemia
MiR-206 levels are upregulated in Waldenström macroglubulinemia cells accounting for modulation of histon deacetylation in part by targeting HAT (Myst3) protein.
[110]
The studies reviewed in Table 1 clearly indicate that the downregulation of miR-206 is associated with poorer patient prognosis, most notably due to the increased metastatic potential of the listed cancers [13, 96, 97] . A potential explanation for this phenomenon may be found in the miR-206 targeting of VEGFA, an important angiogenesis factor, as shown in laryngeal cancer [99] or during zebrafish development [100] . In the latter study, miR-1/206 knockdown zebrafish exhibited larger intersegmental vessel diameter and an increased number of endothelial cells [100] . While this finding needs to be further confirmed on different tumors and in larger cohorts, it may be hypothesized that miR-206 downregulation is a general sign of tumorigenicity which enables neoangiogenesis and the proliferation of tumor cells.
ROLES FOR MIR-206 IN OTHER TISSUES AND DISEASES
Myocardial infarction, heart failure and dilated cardiomyopathy
Various studies indicate that in spite of the muscle-specific character of miR-206, it may also play a pivotal role in the heart muscle [10, 111, 112] and associated conditions. The first study connecting miR-206 to the heart was conducted by Shan et al. [112] and showed that in a mouse model of myocardial infarction, levels of miR-1 and miR-206 are increased in infarcted tissue [112] . The authors suggest that both selected miRs may be involved in apoptotic signaling via IGF-1, leading to cardiomyocyte dysfunction [112] . The same group also showed that myocardial injury is further promoted by miR-206 targeting heat-shock protein 60 (Hsp60) in in vitro and in vivo models of diabetes. An increase in miR-1 and miR-206 was probably induced by a MEK1/2 increase which caused a serum response factor (SRF) increase which induced the expression of the above mentioned miRNAs by binding to specific response elements (RE 2,3,4 for miR-1 and RE5 for miR-206) [111] . A miR-206 increase was also observed in a rat model of heart failure and was even more prominent in mice treated with HMGB1 [10] . Administering HMGB1 improved cardiac function along with collagenolytic activity and decreased cardiac remodeling in experimental animals. These effects may be at least in part explained by an miR-206-induced decrease in tissue inhibitor of metalloproteinase 3 (TIMP-3) levels, thus enabling an increase in matrix metalloproteinase (MMP)2 and MMP9 [10] .
Last but not least, miR-206 is involved in E2F6-induced dilated cardiomyopathy (DCM) [113] . E2F6 represses the EF2/Rb signaling pathway; transgenic mice in which E2F6 expression was sustained until adulthood generally present with DCM leading to heart failure. E2F6 dysregulation in Tg mice was associated with ERK pathway activation leading to an increase in miR-206 levels and Cx43 downregulation leading to DCM and electrical instability [113] (Figure  8 ).
Pulmonary hypertension, COPD and infectious respiratory diseases
It has been suggested previously that the development of pulmonary artery hypertension (PAH) resembles tumor growth to a certain degree, especially due to the devastating proliferation of smooth muscle cells (SMC) [114] . As in the case of tumors, mouse models of pulmonary hypertension have likewise shown downregulated miR-206 levels in examined tissue [14, 115] and upregulated in serum [14] . However, other recently conducted studies present contradictory results. Jalali et al. showed that transfecting miR-206 to pulmonary artery SMCs (PASMCs) caused a decrease in proliferation and cellular migration and an increase in apoptosis, probably due to a decrease in Notch3 signaling. Notch3 is a known repressor of SMC differentiation and miR-206-mediated inhibition results in an increase of SMC differentiation markers, such as calponin and SM specific α-actin. Notch3 is also known to be involved in the pathogenesis of PAH and its inhibition by miR-206 may serve as a potential treatment for PAH in the future [115] . Contradictory results, namely a miR-206-mediated increase in proliferation, has been observed in a study by Yue et al.; miR-206 was shown to target HIF-1a, thus affecting the HIF-1a/Fhl-1 pathway; however, miR-206 transfection paradoxically led to an increase in HIF-1a levels [14] . Future studies are therefore needed to shed more light on the role of miR-206 in PAH pathogenesis.
Furthermore, it is known that PAH often develops as a result of COPD [116] . Increased levels of miR-206 and other muscle-specific miRs were established in COPD patients sera samples; these levels negatively correlated with the function of the quadriceps muscle [16] in which miRNA expression analysis previously showed altered miRNA expression [117] . An increase in serum levels of miR-206 is probably the result of increased muscle turnover, fiber type shift and muscle wasting in COPD patients; circulating miR levels may thus serve as biochemical markers of muscle performance [16] .
MicroRNAs have also been shown to play a role in infectious respiratory diseases as they participate in agent-host interactions [118] . Using porcine models, miRNA expression profiles were found to be changed and miR-206 levels being upregulated in both porcine reproductive and respiratory syndrome virus (PRRSV) [118] and influenza virus [119] infections. Targeting viral RNAs and mRNAs of various inflammatory molecules (determined using computational prediction) indicates potential roles for miR-206 in antiviral response [118, 119] .
In humans, miR-206 serum levels have been proven to be differentially expressed in pertussis patients in comparison with healthy controls [120] . Using a panel of five microRNAs (miR-202, miR-342-5p, miR-206, miR-487b, miR-576-5p), the authors were able to diagnose pertussis with a sensitivity of 97.4 % and a specificity of 94.3 % (cut off 0.707) [120] .
Central nervous system
The brain is the most complex organ in the human body. Various miRNAs were shown to be upregulated or downregulated in distinct parts of the brain, which therefore supports their possible area-specific functions: e.g., miR-206 is detected at higher levels in the cerebellum than in the amygdala, the hippocampus or substantia nigra of adult male rats [121] . In a healthy brain, however, miR-206 can be detected only at very low levels, which may be important for proper neural system development: introducing miR-206 into the oligodendrocyte cell line CG-4 causes a decrease in tubulin polymerization-promoting protein (TPPP)/p25, which results in inhibiting oligodendrocyte differentiation [122] . In a healthy heart, miR-206 levels are barely detectable. In diseased conditions, its levels increase, leading to the apoptosis of the cells after myocardial infarction or in some cases, diabetic cardiomyopathy. In E2F6-induced dilated cardiomyopathy cases, increased miR-206 levels lead to electrical instability. However, heart failure cases, miR-206 overexpression seems to improve cardiac function and positively affect cardiac remodeling.
An increase in miR-206 levels has been observed in various pathological conditions and has been shown to be of theranostic significance [123] [124] [125] . During ischemia/reperfusion injury of the brain [123] , miR-206 levels correlate with infarct size in a rat embolic stroke model, i.e. its levels increase during the first two days, followed by a continuous decrease [15] . Similar correlations were observed in mRNA levels of genes controlled by miR-206 (BDNF, Notch3, Cx43 and Otx2) [15] . MiR-206 levels are also upregulated in Alzheimer's disease; downregulation reached by the delivery of antagomiRs (either directly intraventricularly or indirectly intranasally) caused a prominent increase in memory function, synaptogenesis and neurogenesis in the hippocampus [124] . This may serve as a promising strategy for future Alzheimer's disease management. Last but not least, with respect to schizophrenia, miR-206 SNPs (rs17578796 and rs1700) were associated with the occurrence of this disease [125] . MiR-206 was shown to target genes previously associated with schizophrenia [125, 126] while also targeting the RNAs of several viruses (e.g. coxsackievirus B2, poliovirus 1) which were shown to affect neural cell function [126] .
Other roles of microRNA-206
MicroRNA-206 has already been found to be involved in posttranscriptional regulation of numerous processes throughout the body and seems to be potentially useful in clinical practice. Other organs, diseases and conditions where miR-206 was shown to play a role are summarized in Table 2 and it may be expected that more roles for miR-206 will be provided in the near future. 
Pain control
MiR-206 inhibits the expression of substance P from its mRNA in human mesenchymal-stem-cells-derived neuronal cells.
[128]
MiR-206 levels are changed in dorsal root ganglion and spinal cord dorsal horn in CFA-induced inflammatory response or during sciatic nerve ligation.
[129]
Biorhythms
MiR-206 is a part of the MyoD-miR-206-CLOCK-MyoD regulatory loop and thus participates in circadian rhythms regulation.
[130]
Brown adipose tissue MiR-206 expression is abundant in brown adipocytes and is missing in white adipocytes. This supports the idea that brown adipocytes and myocytes originate from a common cell lineage.
[131]
Liver steatosis MiR-206 suppresses liver X receptor α (LXRα) levels, thus inhibiting lipogenesis and serving as a potential therapeutic tool for future treatment of lipogenesis-associated diseases such as liver steatosis.
[132]
Conclusions
Under physiological conditions, miR-206 may be skeletal-muscle-specific [5, 7] ; however, under pathological conditions, its pleiotropic character is shown to be involved in the pathogenesis of various diseases, including heart failure [10] , different types of tumors such as rhabdomyosarcoma [22, 76, 77] and breast cancer [11, 33, 83, 91] or neurological disorders such as Alzheimer's disease [124] . In most of the above mentioned diseases, miR-206 levels are downregulated, which leads to the recognition of this miRNA as "disease-preventing". In muscle dystrophies, where miR-206 is upregulated, this upregulation seems to be of "self-treating" significance [66, 73] . Alzheimer's disease is an exception from this "disease-preventing rule", since in this case miR-206 upregulation does more harm than good by decreasing levels of BDNF, a molecule involved in neuronal plasticity and other brain functions [124] .
MiR-206's importance is further highlighted by the many factors known to be involved in its regulation. The complex network of regulatory mechanisms results not only in miR-206's tissue-specific expression [7] but also in area-or locality-specific expression as shown in various types of muscle [66, 67] and distinct parts of the brain [121] . Whether these slight differences affect the precise functions of the above mentioned tissues (e.g. by affecting fiber type or neurotransmission), must be determined by future studies.
Using many examples, miR-206 was shown to have great theranostic potential for future clinical practice, serving as a disease biomarker, a disease progression and patient prognosis marker and in some cases even serving as a treatment tool.
To diagnose a disease, more than one miRNA is generally necessary and more miRNAs create a specific pattern which facilitates the ability to distinguish different diseases. While MiR-206 is very often part of these patterns, its elevated circulating levels on their own may also be enough to identify patients with rhabdomyosarcoma [79] or to assess the severity of muscle wasting in patients with COPD [16] .
With respect to the therapeutic potential of miR-206, both currently suggested methods using miR mimics and antagomiRs may be used [133] . Us-ing miR-206 mimics should lead to its level restoration in diseased tissue and the restoration of many target protein levels and thus to an improvement of the disease or its cure. This has already been suggested for rhabdomyosarcoma [76, 77] , muscle dystrophies [73] and pulmonary hypertension [134] . AntagomiR against miR-206 may -on the other hand -offer a promising strategy to deal with Alzheimer's disease [124] .
Using miRNAs as treatment tools is currently becoming a reality since there are biotech companies focusing on the use of miRNAs in diagnostics as well as pharmaceutical companies finalizing preclinical research phases and proceeding to clinical trials. In the case of liver cancer, one of the miRNAs, miR-34a, has already entered Phase I (NCT01829971). In the case of miR-206, MiRagen therapeutics is now in the "lead optimization" phase of research for using this miRNA as treatment for neuromuscular disorders [131] .
In conclusion, miRNAs, and especially miR-206, have great theranostic potential; its real significance will most likely be determined in the very near future.
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